NVCR · NovoCure Limited

Summary

NovoCure Limited announced positive topline results from the Phase 2 PANOVA-4 trial on March 26, 2026, meeting its primary endpoint with a 74.4% disease control rate (DCR) for Tumor Treating Fields therapy combined with atezolizumab, gemcitabine, and nab-paclitaxel in first-line metastatic pancreatic ductal adenocarcinoma, versus 48% in historical control (p<0.001). This supports advancing TTFields therapy for metastatic pancreatic cancer.

Key takeaways

• PANOVA-4 trial met primary endpoint: DCR 74.4% (N=78) vs 48% historical control (N=431 from Phase 3 MPACT), difference 26.4%, 1-sided p<0.001
• Objective response rate (ORR) 34.6% (95% CI: 24.2%-46.2%)
• Median overall survival (OS) 9.7 months (95% CI: 7.9-12.7 months)
• Median TTFields therapy duration 25.6 weeks; median systemic therapy 6 cycles
• TTFields therapy well-tolerated, consistent with prior studies
• Plans to present additional PANOVA-4 results at future scientific forum